anti-CD47

ALX follows Gilead in axing CD47 blood cancer trials as data disappoint
Fierce Biotech
Fri, 08/11/23 - 10:09 am
Gilead Sciences
ALX Oncology
blood cancer
clinical trials
anti-CD47
evorpacept
Gilead's $4.9B oncology bet hit with partial clinical hold, forcing pause of pivotal trials and raising doubts about CD47
Fierce Biotech
Wed, 01/26/22 - 11:12 am
Gilead Sciences
magrolimab
anti-CD47
FDA
clinical trials
oncology
clinical hold
Kahr raises $18M to test CD47 drug with Roche's Tecentriq
Fierce Biotech
Tue, 02/25/20 - 10:24 am
Kahr Medical
anti-CD47
Roche
Tecentriq